Multiple Myeloma – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology's coverage of multiple myeloma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of multiple myeloma for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the developed world.
Clarivate Epidemiology's multiple myeloma forecast will answer the following questions:
- In developing countries, what impact will economic growth and development have on the number of people diagnosed with multiple myeloma per year?
- Of all people diagnosed with multiple myeloma, how many in each country across the developed world are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of multiple myeloma over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.
Clarivate Epidemiology provides at least ten years of forecast data for the following multiple myeloma patient populations:
- Multiple Myeloma Diagnosed Incident Cases – Multiple Myeloma
- Diagnosed Incident Cases by Stage Distribution – Multiple Myeloma
- Diagnosed Incident Cases by symptomatic status- Multiple Myeloma
- Multiple Myeloma Diagnosed 1st Line Drug-Treatable Population
- 1st Line DTP by Transplant-Eligibility Status
- 1st Line Transplant-Eligible Drug-Treatment subpopulation(s)
- 1st Line Transplant-Ineligible Drug-Treatment subpopulation(s)
- 2nd Line DTP Drug-Treatment subpopulation(s)
- Multiple Myeloma Diagnosed 2nd Line Drug-Treatable Population
… and more (details available on request).
Note: coverage may vary by country and region.
Table of contents
- Multiple Myeloma - Epidemiology - Epidemiology Dashboard
- Introduction
- Epidemiology Dashboard
- Introduction
Ullas Ulahannan, MPH., Epidemiologist, Epidemiology. Before joining Clarivate, he worked at Jhpiego (a John Hopkins University affiliate) as a senior program officer evaluating, implementing, and monitoring various health programs in collaboration with the state and central governments of India. His qualifications include a master’s degree in public health from Manipal University, Manipal, and a bachelor’s degree in nursing from Rajiv Gandhi University of Health Sciences, Bangalore
Surup Dey, M.L.T., M.P.H., is an epidemiologist at Clarivate. A former microbiologist, he was involved in the diagnosis of rare hematological disorders. Mr. Dey has a background in medical laboratory science from Christian Medical College in Vellore and earned a postgraduate degree in public health specializing in epidemiology from Manipal University. He specializes in real-world data analysis, cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer.